Deep Learning seems to be the magical word today in biology and medicine. This technology is used for DNA exploration, pictures interpretation or even to predict future diseases. Deep Genomics is going further and annonces to use of Deep Learning for early-stage development of drugs for Mendelian disorders. As the founder, Brendan Frey, says, it could be a new step in drugs developement, and maybe a “really massive shake-up of pharmaceuticals” !

Deep Genomics, a Canadian company that uses machine learning to trace potential genetic causes for disease, announced Tuesday that it’s getting into drug development. It joins a growing list of AI companies betting that their techniques can help produce powerful new drugs by finding subtle signals in huge quantities of genomic data.

Source: An AI-Driven Genomics Company Is Turning to Drugs – MIT Technology Review

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.